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doi:10.1016/j.jfma.2012.01.020Background/Purpose: Radiotherapy is a crucial treatment for acromegalic patients with
growth hormone (GH)-secreting pituitary tumors. However, its effect takes time. We retro-
spectively reviewed the long-term outcome of linear accelerator stereotactic radiosurgery
(LINAC SRS) for patients with acromegaly from the perspective of biochemical remission and
associated factors.
Methods: Twenty-two patients presenting with residual or recurrent (GH)-secreting functional
pituitary tumor between 1994 and 2004 who received LINAC SRS were enrolled and followed up
for at least 3 years. Residual or recurrent tumor was defined as persistent elevated GH or
insulin-like growth factor-1 (IGF-1) level and image-confirmed tumor after previous surgical
treatment. Biochemical remission was defined as fasting GH less than 2.5 ng/mL with normal
sex-and-age adjusted IGF-1.
Results: The mean follow-up period was 94.7 months (range 36e161 months). Overall mean
biochemical remission time was 53 months (median 30 months). Biochemical control was
achieved in 15 patients (68.2%) over the follow up period. One patient experienced recurrenceof Neurosurgery, Chang Gung Memorial Hospital, Taipei, Taiwan.
com (C.-N. Chang).
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Radiosurgical outcome in acromegalic patients 417after SRS and underwent another operation. Initial GH at diagnosis and pre-SRS GH correlated
with biochemical control (pZ 0.005 and p < 0.0001, respectively). Further evaluation demon-
strated that biochemical control stabilized after 7.5 years. Overall post-SRS hormone deficit
persisted in five patients (22.7%).
Conclusion: In comparison to other radiosurgery modalities, LINAC radiosurgery also provides
a satisfactory outcome. SRS has maximum effect over the first 2 years and stabilizes after
7.5 years. Moreover, SRS elicits long-term biochemical effects and requires longer follow-up
for better biochemical remission.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Growth hormone (GH)-secreting pituitary tumors account
for approximately 20% of pituitary tumors. Although most
are benign, inadequate treatment may lead to clinical
acromegaly, which increases mortality and morbidity.1,2
Therefore, in order to achieve normal endocrine status,
multiple methods have been established, including medi-
cation, operation, and radiosurgery. Surgery such as
transsphenoidal adenomectomy has been used as a first-
line treatment for the GH-secreting pituitary tumor with
a good tumor control rate.3 Somatostatin analog (SSA),
dopamine analog, and GH receptor antagonist medications
provide 44%, 10%,4,5 and 60%6 endocrine remission,
respectively. Radiosurgery, first introduced in 1951 by Lars
Leksell,7 has been reported to have a 68e100% tumor
control rate and nearly 96% endocrine remission rate.8
The long-term effects of radiosurgery on GH-secreting
pituitary tumors have been investigated.9,10 The slow-
growing nature of the tumor leads to a longer effect of
the radiation. The efficacy of radiosurgery on endocrine
remission is thought to continue for more than 5 years, but
the specific time of the radiosurgery effects remained
unknown. Therefore, in the present study, we retrospec-
tively reviewed the long-term outcome of linear acceler-
ator radiosurgery for patients with acromegaly in our
hospital with an emphasis on chronological biochemical
remission. We further surveyed the possible risk factors and
estimated the effective duration of radiosurgery.
Material and methods
Patient population
We retrospectively collected data from patients who
underwent radiosurgery from July 1994 to July 2004. The
inclusion criteria were GH-secreting pituitary adenoma and
clinical presentation of acromegaly. Acromegaly was diag-
nosed by clinical observation according to the chart and
fasting GH over 5 ng/mL or GH over 1 ng/mL in the oral
glucose tolerance test (OGTT). In addition, magnetic reso-
nance imaging (MRI) was used for imaging diagnosis.
In total, 1114 patients underwent stereotactic radio-
surgery (SRS) from 1994 to 2004 at our neurosurgical insti-
tute. Among them, 117 were diagnosed with pituitary
tumor, and GH-secreting pituitary adenoma was found in 28
patients. In our hospital, patients with GH-secreting pitui-
tary adenoma received transsphenoidal adenectomy as
standard primary treatment. Six patients were excludeddue to incomplete data and follow-up less than 3 years. All
patients who received SSA (n Z 11; octreotide long-acting
20 mg intramuscular every month) stopped taking medica-
tion 4 months before SRS due to possible radioprotective
effects.11
Radiosurgery
Patients’ position and tumor localization were fixed with
a Cosman-Roberts-Wells stereotactic frame system.
A computed tomography scan with a slice thickness of 3 mm
was used to localize both the target and the normal critical
structures. The treatment target included the gross visible
tumor in MRI images and was supplemented by pre-
treatment MRI. The target volume ranged from 0.19 cm3
to 4.86 cm3 with a mean (SD) of 1.38 cm3 (1.23). Linear
accelerator SRS (LINAC SRS) was performed for the
following indications: 1) primary, residual, or recurrent
pituitary tumor; 2) tumor less than 3 cm in diameter; and 3)
distance from tumor to the optic apparatus greater than 5
mm. Target localization was performed with MRI. The
dosage depended mainly on target distance from optic
apparatus; the dosage to the optic apparatus was kept less
than 800 cGy. The mean tumor dosage was 2295 cGy
(561). The mean 80% isodose was 1455 cGy (315).
Clinical evaluation and follow-up
All patients were followed up for more than 3 years. The
criteria of biochemical remission were fasting GH less than
2.5 ng/mL with normal sex- and age-adjusted insulin
growth factor-1 (IGF-1). Additional fasting GH less than
1 ng/mL was listed due to different criteria of biochemical
remission in different studies.
Hormone activity was followed by measuring human
Growth Hormone (hGH), IGF-1, Tri-iodothyronine (T3),
Thyroxine (T4), Thyroid-Stimulating Hormone (TSH), Adre-
nocorticotropic hormone (ACTH), Luteinizing Hormone
(LH), Follicle-stimulating hormone (FSH), testosterone (in
men), and prolactin. During follow-up, GH and IGF-1 were
the primary measures of tumor activity. Tumor size was
followed using MRI or computed tomography scan. All
patients underwent ophthalmologic examination to eval-
uate visual field and visual acuity.
Statistical analysis
Statistical analysis was performed with SPSS (SPSS Inc,
Version 16, Chicago, UK, USA) and GraphPad Prism
Figure 1 The proportion of patients in biochemical remission
throughout the follow-up period. A significant difference was
observed by using different criteria of biochemical remission
(p Z 0.0008). GH Z growth hormone.
418 J.-L. Yan et al.(GraphPad Software, Inc. California, USA). Time to
biochemical remission was calculated as a proportion using
the Kaplan-Meier method. The dependent factor for
correlation analysis was time to biochemical remission.
Univariate analyses of variables including age, sex, pre-SRS
GH, GH at diagnosis, radiation dosage, tumor volume, and
use of SSA were performed using the log-rank test, and
correlations were analyzed by Spearman’s test. The
percentage decrease in GH was calculated with an expo-
nential regression curve to estimate the GH decrease
plateau. The prescribed level of statistical significance (p
value) was 0.05.
Results
General characteristics
General patient characteristics are summarized in Table 1.
A total of 22 patients were included in this study. FourteenTable 1 General characteristics of acromegalic patients.
General characteristics
Male, n (%) 8 (36.4%)
Female, n (%) 14 (63.6%)
Age at diagnosis (y), mean  SD 36.5  7.89
Age at diagnosis (y), median, range 35.5, 22e50
Follow-up (months), mean  SD 94.68  41.1
Follow-up (months), median, range 98, 36e161
Follow up >5 years, n (%) 17 (77.3%)
Previous operation, n (%) 21 (95.5%)
OP to SRS (months), mean  SD 27.7  30.03
OP to SRS (months), median, range 15, 1e98
Use of octreotide, n (%) 11 (50%)
SRS dose (cGy)
80% isodose, mean  SD 1455  315
80% isodose, median, range 1500, 800e2000
Maximal dose, mean  SD 2295  561
Maximal dose, median, range 2290, 1370e3592
Tumor volume (cm3), mean  SD 1.38  1.23
Tumor volume (cm3), median, range 1.1, 0.19e4.86
Initial GH (ng/mL), mean  SD 42.6  30.2
Initial GH (ng/mL), median, range 46.9, 5.02e363.98
Pre-SRS GH (ng/mL), mean  SD 21.3  16.94
Pre-SRS GH (ng/mL), median, range 14.5, 3.46e59.1
Post-SRS GH (ng/mL), mean  SD 2.25  1.58
Post-SRS GH (ng/mL), median, range 1.85, 0.53e5.94
Biochemical remissiona
Group A, n (%) 6 (27.3%)
Group B, n (%) 15 (68.2%)
Biochemical remission (months)a
Group A, mean  SD 26  20.01
Group A, median, range 23.5, 7e62
Group B, mean  SD 53  50.74
Group B, median, range 30, 7e157
Post-SRS visual change 0
a Group A: fasting GH< 1 ng/mL; Group B: fasting GH< 2.5 ng/
mL. GHZ growth hormone, OPZ operation, SRSZ stereotactic
radiosurgery.patients (63.6%) were female, and eight were male. The
mean age at diagnosis was 36.5 years. Twenty-one of the
patients (95.5%) underwent transsphenoidal adenomec-
tomy of the pituitary tumor as the primary treatment. One
patient received SRS as the primary treatment due to poor
nasal hygiene after consultation with the Ear Nose Throat
doctor (ENT doctor).
The mean time from operation to SRS was 27.7 months.
The mean follow-up after SRS was 94.68 months (range
36e161 months), and 17 patients (77.3%) received follow-
up for more than 5 years after radiosurgery. Eleven patients
(50%) received SSA treatment. Mean tumor volume was 1.38
cm3. Five patients required long-term hormone replace-
ment after SRS; one presented with hypogonadism and the
other four needed long-term cortisol replacement. No
patients experienced visual field changes during post-SRS
follow-up. No disease-related mortality was noted during
follow-up.
Long-term effect of SRS on biochemical remission
Biochemical remission was achieved in 15 patients (68.2%)
over the follow-up period. The mean duration from SRS to
biochemical remission (GH < 2.5 ng/mL) was 53 months.Figure 2 This figure shows the decrease in GH as
a percentage of baseline. The plateau of regression curve is
shown by the dotted line. The decrease in GH was stable at 7.5
years after stereotactic radiosurgery. GH Z growth hormone.
Table 2 Factors associated with biochemical remission.
Factors P value Hazard ratio
Age 0.929
Sex 0.908
GH at diagnosis 0.001 4.409
Pre-SRS GH 0.027 3.239
Time from OP to SRS 0.382
Radiosurgery dosage 0.56a, 0.629b
Tumor volume 0.18
Use of octreotide 0.544
Initial and pre-SRS GH levels are significantly related to the
duration of biochemical remission. GH Z growth hormone,
OP Z operation, SRS Z stereotactic radiosurgery.
a Maximal SRS dosage.
b 80% SRS isodose.
Radiosurgical outcome in acromegalic patients 419Overall biochemical remission in the two categories is
shown in Fig. 1. Approximately 50% patients achieved
biochemical remission at the 82nd month. One patient had
recurrence during follow-up and underwent a second
operation for tumor excision.
The decrease in GH as a percentage of the baseline
value is shown in Fig. 2. The maximal percentage decrease
in GH occurred during the first 2 years after SRS. An expo-
nential regression curve of percentage decrease in GH was
calculated to estimate the plateau of the decrease, which
was found to be 14.6% of baseline. The plateau indicates no
change in GH after 90 months, indicating the decrease inFigure 3 There was significant difference of biochemical remissio
after year 4 (C). Although patients who needed octreotide after SR
(D), it might take years to achieve the effect. SRS Z stereotacticGH becomes stable at 90 months after radiosurgery. The
increase in GH at month 36 may be due to the recurrent
patient, who had a fourfold GH increase compared with
baseline.
Factors associated with biochemical remission
Factors associated with biochemical remission are shown in
Table 2. Univariate analysis showed both GH at diagnosis and
pre-SRS GH levels to be highly associated with the time to
biochemical remission (p < 0.05). In addition, Spearman’s
correlation test demonstrated these factors to positively
correlate with hazard ratio (4.409 and 3.239, respectively),
indicating higher GH levels at diagnosis and before SRS
necessitate more time to reach biochemical remission. In
contrast, age, sex, time from operation to SRS, radiosurgery
dosage, tumor volume, and use of sandostatin do not have
significant effects to the biochemical remission.
Discussion
SRS is currently a widely used modality for treatment of
pituitary tumors. However, the biochemical effects of
radiosurgery usually take time. Pollock et al.10 suggested
that patients with GH-producing pituitary adenomas should
not undergo further radiation therapy or surgery for at least
5 years after radiosurgery because GH levels continue to
normalize over that period. However, the time required for
GH to reach a stabilized level after radiosurgery still
remained unknown. In our study, we followed the decreasen in the first and second years (A, B). The difference diminished
S may have fair biochemical outcome in the overall follow-up
radiosurgery.
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estimated plateau at the 90th month after SRS. This finding
may provide helpful information for post-SRS clinical
follow-up.
A question remains regarding how to proceed if GH dose
not normalize within 90 months after radiosurgery. Should
we go further with other management options or just wait
for the long-term effect?
In our study, we observed the greatest effect within the
first 2 years, which is comparable with most previous
studies.1216 We found GH declined by approximately 50%
in the first 2 years. In addition, 40% of patients had GH
levels less than 2.5 ng/mL within 2 years. Therefore, it is
worthy to wait for the SRS effects in the first 2 years. After
the first 2 years, other treatment modalities may be used
individually on different patients.
In our hospital, most patients who received octreotide
were administrated the drug after radiosurgery followed by
unsatisfactory clinical outcome. Further study on the
difference between patients who did or did not use
octreotide showed there was no difference on the overall
biochemical outcome (Fig. 3D). The result may be due to
a significant variation in GH levels at diagnosis (31.47 ng/
mL and 53.73 ng/mL respectively in patients without and
with octreotide after SRS). This may imply that patients
with higher initial GH levels can have fair biochemical
control by using octreotide after SRS. On analysis of the
chronological effect, we found a slower biochemical
remission in patients who needed to receive additional
octreotide. These patients have worse biochemical control
on the first 1 and 2 years and have equal biochemical results
4 years after (Fig. 3AeD).
In our study, we concluded that GH at diagnosis and pre-
SRS GH status may have a significant influence on
biochemical remission. Higher GH levels necessitate
a longer time to reach biochemical remission. The same
result has been shown in many studies.10,17 No significant
association between biochemical remission and age, sex, or
radiation dosage was observed. However, other studies
have reported a positive relationship between radiation
dosage and GH outcome.
The diagnosis of acromegaly has now been more strictly
defined using basal GH, GH after OGTT, and IGF-1. The
consensus statement of the European Society of Endocri-
nology suggests the post-operative criteria for biochemical
remission are nadir GH less than 0.4 ng/mL, post-OGTT GH
less than 1 ng/mL, and normal age- and sex-adjusted IGF-1.18
However, many recent studies used normal age-and-sex
adjusted IGF-1 accompanied by basal GH less than
2e2.5 ng/mL as the biochemical remission criteria.10,17,19,20
Few centers use OGTT as a standard criterion for post-
radiosurgery biochemical remission. Pollock et al.10 sug-
gested that OGTT may be impractical in daily practice, and
Peaceyet al.21 suggested that radiation therapymayalterGH
feedback regulation.
Our study has some limitations. It was not a prospective
trial, and the treatment policy slightly differed in some
patients due to the different period of clinical course. This
difference might contribute some bias to our conclusions,
but the long investigation period of the study remains
valuable.We believe that SRS is a safe and effective modality to
treat GH-producing pituitary tumor. SRS had maximum
effect in the first 2 years and stabilized after 7.5 years.References
1. Holdaway IM, Bolland MJ, Gamble GD. A meta-analysis of the
effect of lowering serum levels of GH and IGF-I on mortality in
acromegaly. Eur J Endocrinol 2008;159:89e95.
2. Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing
mortality in acromegaly. J Clin Endocrinol Metab 2004;89:
667e74.
3. Laws Jr ER, Thapar K. Pituitary surgery. Endocrinol Metab Clin
North Am 1999;28:119e31.
4. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB,
Kleinberg D, et al. Guidelines for acromegaly management: an
update. J Clin Endocrinol Metab 2009;94:1509e17.
5. Melmed S, Casanueva FF, Cavagnini F, Chanson P, Frohman L,
Grossman A, et al. Guidelines for acromegaly management. J
Clin Endocrinol Metab 2002;87:4054e8.
6. van der Lely AJ, Kopchick JJ. Growth hormone receptor
antagonists. Neuroendocrinology 2006;83:264e8.
7. Leksell L. The stereotaxic method and radiosurgery of the
brain. Acta Chir Scand 1951;102:316e9.
8. Witt TC. Stereotactic radiosurgery for pituitary tumors. Neu-
rosurg Focus 2003;14:e10.
9. Jane Jr JA, Vance ML, Woodburn CJ, Laws Jr ER. Stereotactic
radiosurgery for hypersecreting pituitary tumors: part of
a multimodality approach. Neurosurg Focus 2003;14:e12.
10. Pollock BE, Jacob JT, Brown PD, Nippoldt TB. Radiosurgery of
growth hormone-producing pituitary adenomas: factors associ-
ated with biochemical remission. J Neurosurg 2007;106:833e8.
11. Landolt AM, Haller D, Lomax N, Scheib S, Schubiger O,
Siegfried J, et al. Octreotide may act as a radioprotective
agent in acromegaly. J Clin Endocrinol Metab 2000;85:1287e9.
12. Landolt AM, Lomax N. Gamma knife radiosurgery for prolacti-
nomas. J Neurosurg 2000;93(Suppl. 3):14e8.
13. Laws Jr ER, Vance ML. Radiosurgery for pituitary tumors and
craniopharyngiomas. Neurosurg Clin N Am 1999;10:327e36.
14. Pollock BE, Nippoldt TB, Stafford SL, Foote RL, Abboud CF.
Results of stereotactic radiosurgery in patients with hormone-
producing pituitary adenomas: factors associated with endo-
crine normalization. J Neurosurg 2002;97:525e30.
15. Sheehan JM, Vance ML, Sheehan JP, Ellegala DB, Laws Jr ER.
Radiosurgery for Cushing’s disease after failed transsphenoidal
surgery. J Neurosurg 2000;93:738e42.
16. Zhang N, Pan L, Wang EM, Dai JZ, Wang BJ, Cai PW. Radio-
surgery for growth hormone-producing pituitary adenomas.
J Neurosurg 2000;93(Suppl. 3):6e9.
17. Castinetti F, Taieb D, Kuhn JM, Chanson P, Tamura M, Jaquet P,
et al. Outcome of gamma knife radiosurgery in 82 patients with
acromegaly: correlation with initial hypersecretion. J Clin
Endocrinol Metab 2005;90:4483e8.
18. Melmed S, Casanueva F, Cavagnini F, Chanson P, Frohman LA,
Gaillard R, et al. Consensus statement: medical management
of acromegaly. Eur J Endocrinol 2005;153:737e40.
19. Attanasio R, Epaminonda P, Motti E, Giugni E, Ventrella L,
Cozzi R, et al. Gamma-knife radiosurgery in acromegaly: a 4-
year follow-up study. JClin EndocrinolMetab 2003;88:3105e12.
20. Jezkova J, Marek J, Hana V, Krsek M, Weiss V, Vladyka V, et al.
Gamma knife radiosurgery for acromegalydlong-term experi-
ence. Clin Endocrinol (Oxf) 2006;64:588e95.
21. Peacey SR, Toogood AA, Shalet SM. Hypothalamic dysfunction
in "cured" acromegaly is treatment modality dependent. J Clin
Endocrinol Metab 1998;83:1682e6.
